Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
16-week Disease Control Rate
4-week
Yes
Jacques Cadranel
Principal Investigator
APHP Hopital Tenon (Pneumologie) - Paris - France
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
IFCT-0504
NCT00384826
September 2006
July 2013
Name | Location |
---|